Leukemia (Pediatric) Clinical Trials

Duarte : City of Hope

COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Savannah : Memorial University Medical Center

AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

Savannah : Memorial University Medical Center

AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Savannah : Memorial University Medical Center

AALL07P1: Bortezomib and Combination Chemotherapy in Treating Younger Patients with Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Savannah : Memorial University Medical Center

AALL08B1: Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Savannah : Memorial University Medical Center

AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

Savannah : Memorial University Medical Center

AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789) in the Very High Risk Stratum.

Savannah : Memorial University Medical Center

ACCL0993: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infection in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Savannah : Memorial University Medical Center

ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial

Savannah : Memorial University Medical Center

ADVL0921: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation

Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias